FDA Approves Procalcitonin Biomarker Test to Aid Antibiotic Decision Making

April 12, 2017

The FDA recently announced the expansion of the use of the Vidas Brahms PCT Assay (bioMérieux) to help clinicians make important decisions regarding the optimal use of antibiotics in two common clinical situations: lower respiratory tract infections (LRTI) and sepsis. This is the first test to use procalcitonin (PCT) as a biomarker to help make antibiotic management decisions in patients with these conditions.

Read the full story here